ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 849

Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis

Iago Pinal-Fernandez1, Berta Ferrer-Fabregas2, Ernesto Trallero-Araguas1, Eva Balada1, Maria Angeles Martinez3, Jose Cesar Milisenda4, Gloria Aparicio-Español5, Moises Labrador-Horrillo1, Vicente Garcia-Patos1, Josep Maria Grau-Junyent4 and Albert Selva O'Callaghan6, 1Internal Medicine, Autoimmune Diseases Unit. Vall d´Hebron Hospital, Barcelona, Spain, 2Pathology, Vall d´Hebron, Barcelona, Spain, 3Immunology, Immunology Department, Barcelona, Spain, 4Muscle Research Group and Ciberer, Hospital Clinic Provincial, Barcelona, Spain, 5Dermatology, Vall d´Hebron Hospital, Barcelona, Spain, 6Internal Medicine, Hospital Universitari General Vall d'Hebron, Barcelona, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, Autoimmunity, Cancer, dermatomyositis and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Muscle Biology, Myositis and Myopathies

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: To analyze the influence of genetic alterations and differential expression of the TIF1 genes in the pathophysiology of cancer-associated myositis (CAM).

Methods: Whole exome sequencing of paired blood and tumor DNA samples from anti-TIF1g positive CAM patients and controls were analyzed for the presence of somatic mutations and copy number changes in the TIF1 genes. To better understand the genesis and maintenance of the autoimmune process we also studied the expression of TIF1g in the different tissues involved in CAM (skin, muscle, and tumor) calculating the immunohistochemical H-score.

Results: Six out of 7 tumors from anti-TIF1g positive patients showed somatic mutations or loss of heterozygosity in one or more of the 4 TIF1 genes compared with just one myositis control tumor (86% vs. 17%, p=0.03). Compared with control tumors from non-myositis patients, tumors from both anti-TIF1g positive (H-score 255 vs. 196, p=0.01) and anti-TIF1g negative CAM patients (H-score 251 vs. 152, p=0.03) showed more intense TIF1g staining, without significant differences between anti-TIF1g positive and negative patients. Compared with anti-TIF1g negative patients, TIF1g muscle staining was more intense in anti-TIF1g positive patients (H-score 22 vs. 5, p=0.03), while the skin of both myositis and control patients showed intense TIF1g staining.

Conclusion: Mutations of TIF1 genes in tumors with high expression of TIFg may trigger myositis. We hypothesize that an intense antineoplastic immune response may cause a rapid depletion of tumor neo-antigen shifting the target of immune cells experiencing affinity maturation towards the wild-type form of the antigen, abundantly expressed in the skin and muscle of these patients.


Disclosure: I. Pinal-Fernandez, None; B. Ferrer-Fabregas, None; E. Trallero-Araguas, None; E. Balada, None; M. A. Martinez, None; J. C. Milisenda, None; G. Aparicio-Español, None; M. Labrador-Horrillo, None; V. Garcia-Patos, None; J. M. Grau-Junyent, None; A. Selva O'Callaghan, None.

To cite this abstract in AMA style:

Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martinez MA, Milisenda JC, Aparicio-Español G, Labrador-Horrillo M, Garcia-Patos V, Grau-Junyent JM, Selva O'Callaghan A. Tumor TIF1 Mutations and Loss of Heterozygosity Related to Cancer Associated Myositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tumor-tif1-mutations-and-loss-of-heterozygosity-related-to-cancer-associated-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tumor-tif1-mutations-and-loss-of-heterozygosity-related-to-cancer-associated-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology